Download Files:
Lucerastat
$200 – $2,125
Products Details
Product Description
– Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study[1][2].
Web ID
– HY-106392
Storage Temperature
– -20°C (Powder, sealed storage, away from moisture)
Shipping
– Blue Ice
Applications
– Metabolism-protein/nucleotide metabolism
Molecular Formula
– C10H21NO4
References
– [1]Sanne J van der Veen, et al. Developments in the Treatment of Fabry Disease. J Inherit Metab Dis. 2020 Feb 21.|[2]R.W.D. Welford, et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence.
CAS Number
– 141206-42-0
Molecular Weight
– 219.28
SMILES
– O[C@H]1[C@@H](CO)N(CCCC)C[C@H](O)[C@H]1O
Clinical Information
– Phase 3
Research Area
– Metabolic Disease
Solubility
– DMSO : 22 mg/mL (ultrasonic;warming;heat to 80°C)|H2O : 24 mg/mL (ultrasonic;warming;heat to 80°C)
Target
– Glucosylceramide Synthase (GCS)
Pathway
– Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
